Year 2022 / Volume 114 / Number 6
Submission and tracking of manuscripts
Instructions to authors

Submission and tracking

REED Journal

REED Journal

Play video

Year 2022 / Volume 114 / Number 6


Effects of everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study


Miguel Gómez-Bravo, Martín Prieto Castillo, Miquel Navasa, Gloria Sánchez-Antolín, Laura Lladó, Alejandra Otero, Trinidad Serrano, Carlos Jiménez Romero, Miguel García González, Andrés Valdivieso, María Luisa González-Diéguez, Manuel de la Mata, José A. Pons, Magdalena Salcedo, Juan M. Rodrigo, Valentín Cuervas-Mons, Antonio González Rodríguez, Mireia Caralt, Fernando Pardo, Evaristo Varo Pérez, Gonzalo Crespo, Ángel Rubin, Magda Guilera, Anna Aldea, Julio Santoyo,

Background and Aim: reduction in calcineurin inhibitor levels is considered crucial to decrease the incidence of kidney dysfunction in liver transplant (LT) recipients. The aim of this study was to evaluate the safety and impact of everolimus plus reduced tacrolimus (EVR + rTAC) vs. mycophenolate mofetil plus tacrolimus (MMF + TAC) on kidney function in LT recipients from Spain. Methods: the REDUCE study was a 52-week, multicenter, randomized, controlled, open-label, phase 3b study in de novo LT recipients. Eligible patients were randomized (1:1) 28 days post-transplantation to receive EVR + rTAC (TAC levels ≤ 5 ng/mL) or to continue with MMF + TAC (TAC levels = 6-10 ng/mL). Mean estimated glomerular filtration rate (eGFR), clinical benefit in renal function, and safety were evaluated. Results: in the EVR + rTAC group (n = 105), eGFR increased from randomization to week 52 (82.2 [28.5] mL/min/1.73 m2 to 86.1 [27.9] mL/min/1.73 m2) whereas it decreased in the MMF + TAC (n = 106) group (88.4 [34.3] mL/min/1.73 m2 to 83.2 [25.2] mL/min/1.73 m2), with significant (p < 0.05) differences in eGFR throughout the study. However, both groups had a similar clinical benefit regarding renal function (improvement in 18.6 % vs. 19.1 %, and stabilization in 81.4 % vs. 80.9 % of patients in the EVR + rTAC vs. MMF + TAC groups, respectively). There were no significant differences in the incidence of acute rejection (5.7 % vs. 3.8 %), deaths (5.7 % vs. 2.8 %), and serious adverse events (51.9 % vs. 44.0 %) between the 2 groups. Conclusion: EVR + rTAC allows a safe reduction in tacrolimus exposure in de novo liver transplant recipients, with a significant improvement in eGFR but without significant differences in renal clinical benefit 1 year after liver transplantation.

Reader rating: Rate this article:
Share Button
Send by e-mail

New comment

Security code:
CAPTCHA code image
Speak the codeChange the code


No hay comentarios para este artículo.
Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
© 2022 The Spanish Journal of Gastroenterology